Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer

Breast Cancer: Targets and Therapy

Volumn 3, Issue , 2011, Pages 139-150

  Merriam, Priscilla ^a   Sikov, William M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Breast neoplasm; ErbB2; Estrogen receptor; Lapatinib; Letrozole

Indexed keywords

EID: 84897539263     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S12150     Document Type: Article

References (58)

1. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5-23.
2. Witters L, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep. 2002;9(6):1163-1166.
3. Berry DA, Cirrincione CC, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658-1667.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
6. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101-2109.
7. Spector NL, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1abd ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005;23(11):2502-2512.
8. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-638.
9. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2- negative advanced or metastatic breast cancer. Ann Oncol. 2008;19(6): 1068-1074.
10. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009;20(6):1026-1031.
11. Iwata H, Toi M, Fujiwara Y, et al. Phase II clinical study of lapatinib (GW57206) in patients with advanced or metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2006;100 Suppl 1:S68.
12. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999-3005.
13. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11(13): 4741-4748.
14. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20(6):1467-1472.
15. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
16. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9(1):23-28.
17. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogena nd progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the ATAC trial. J Clin Oncol. 2008;26(7):1059-1065.
18. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000;18(20):3471-3479.
19. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808-3816.
20. Robertson JFR, Lindemann JPO, Llombart-Cussac A, et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST' study. Cancer Res. 2010;70(24 Suppl):S1-3.
21. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen- resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24(2):85-95.
22. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10(12):2435-2446.
23. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen sensitivity in vivo. Breast Cancer Res Treat. 1995;34(2): 97-117.
24. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2):142-153.
25. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000;60(20):5887-5894.
26. Weinstein-Oppenheimer CR, Burrows C, Steelman LS, McCubrey JA. The effects of beta-estradiol on Raf activity, cell cycle progression, and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol Ther. 2002;1(3):256-262.
27. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl. 2001;Suppl 36:232-246.
28. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition bewteen the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene. 2000;19(4):490-497.
29. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer [abstract]. Cancer Res. 2010;70(24 Suppl):S3-3.
30. Gianni L, Pienkowski T, Im YH, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere') [abstract]. Cancer Res. 2010;70(24 Suppl): S3-2.
31. Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer. 2005;6(3):247-252.
32. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(18S):512.
33. Leary AF, Drury S, Detre S, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res. 2010;16(15): 1486-1497.
34. Chu QS, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008;14(14):4484-4490.
35. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27(33):5538-5546.
36. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2s hormone receptor-positive metastatic breast cancer. Oncologist. 2010; 15(2):122-129.
37. Platek GT, Koehler M, Gagnon R, et al. Relevance of serum HER2 extracellular domain (sECD) in EGF30008, a study of letrozole 88lapatinib in patients (pts) with hormone-receptor positive (HRi) metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2009;27(15S):1019.
38. O'Rourke L, Pegram M, Press M, et al. First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HRr) metastatic breast cancer (MBC): subgroup analyses of borderline FISHm, IHC 2I, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008 [abstract]. J Clin Oncol. 2009; 27(15S):1062.
39. Finn RS, Press M, Dering J, et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008 [abstract]. J Clin Oncol. 2009; 27(15S):1018.
40. Frassoldati A, Guarneri V, Bottini A, et al. Preplanned first-step analysis of LET-LOB neoadjuvant study: a double-blind randomized phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HRHve operable breast cancer [abstract]. J Clin Oncol. 2009;27(15S):570.
41. Ro J, Pippen J, Pivot X, et al. Safety of first-line letrozole compared with lapatinib plus letrozole in patients with postmenopausal hormone receptor positive metastatic breast cancer: EGF30008 Study [abstract]. Cancer Res. 2009;69(24 Suppl 3):5094.
42. Zembryki D, Gomez H, Koehler M, et al. Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2009; 27(15S):1095.
43. Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2J metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010;15(9):944-953.
44. Sherif BN, Sherrill B, Amonkar M, et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2ppmetastatic breast cancer (MBC): a quality-of-life (QOL) analysis [abstract]. J Clin Oncol. 2009;27(15S):1039.
45. Hastings V, Delea TE, Amonkar M, Lykopoulos K, Diaz J, Johnston S. Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET LAP) versus anastrozole plus trastuzumab (ANALTZ) as first-line treatment for postmenopausal women with HER2ffand HRa metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective [abstract]. J Clin Oncol. 2010;28(15S):1035.
46. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007;102(1):43-49.
47. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33): 5529-5537.
48. Huober J, Fasching P, Paepke S, et al. Letrozole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer - results of the eLEcTRA trial [abstract]. Cancer Res. 2009;69(24 Suppl 3):4094.
49. Koeberle D, Ruhstaller T, Jost L, et al. Can resistance to trastuzumab be reversed by endocrine therapy? Results from a proof-of-principle trial in postmenopausal patients with hormonal receptor (HR) positive, HER-2 positive advanced breast cancer (SAKK 23/03) [abstract]. Cancer Res. 2010;70(24 Suppl):P3-14-16.
50. Schwartz G, Borges V, Weiselberg L, Elias A, Budman D. Lapatinib restores endocrine sensitivity in selected patients with estrogen receptor (ER) positive metastatic breast cancer [abstract]. Cancer Res. 2009;69(24 Suppl 3):3089.
51. Burstein HJ, Barry WT, Cirrincione C, et al. CALGB 40302: Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: a double-blinded, placebo-controlled, randomized phase III study [abstract]. Cancer Res. 2001;70:PD05-01.
52. Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol. 2007;25(21): 3001-3014.
53. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2006; 11(1):3-11.
54. Gutteridge E, Agrawal A, Nicholson R, Leung Cheung K, Robertson J, Gee J. The effects of gefitinib in tamoxifen-resistant and hormoneinsensitive breast cancer: a phase II study. Int J Cancer. 2010;126(8): 1806-1816.
55. Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16(6):1904-1914.
56. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25(25):3816-3822.
57. O'Shaughnessy J, Blackwell KL, Burstein H. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2HHmetastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol. 2008;26(15S):1015.
58. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993-1999.